Literature DB >> 19277811

Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review.

Jean-Cyr Yombi1, Bernard Vandercam, Dunja Wilmes, Jean-Emile Dubuc, Anne Vincent, Pierre-Louis Docquier.   

Abstract

Osteonecrosis of the femoral head (ONFH) typically affects relatively young, active patients and frequently follows an unrelenting course resulting in considerable loss of function. In human immunodeficiency virus-infected patients, ONFH is a growing problem. Etiology, pathogenesis, and treatment of ONFH in these patients remain controversial. We analyzed retrospectively patients with ONFH in a series of 815 patients followed in our AIDS reference center. Six patients out of the 815 were affected by ONFH (0.74%). The sex ratio was 1. Two of the six patients (33.3%) had no evidence of risk factor, whereas four patients (66.6%) had risk factors. One patient had three cumulated risk factors which were corticosteroids, chemotherapy, and radiotherapy. For this patient, the onset time for ONFH was shorter (36 months). It is difficult to attribute the effect to any single class of antiretroviral agents because combination therapy is standard of care, and a change in therapies is common. All classes of antiretroviral drugs have been used: protease inhibitors (mean use duration of 15.2 months before the ONFH onset), non-nucleoside reverse transcriptase inhibitors (12 months), and nucleoside reverse transcriptase inhibitors (40.5 months). ONFH was bilateral in four cases (66.6%) and unilateral in two cases (33.3%). One patient had other osteonecrosis location (both shoulders). ONFH was classified on plain radiography stage IV in five patients and stage III in one patient. All patients received initial medical treatment. It consisted of painkillers and non-weight bearing of the hip. All were finally operated on by total hip arthroplasty (THA). The average interval between ONFH diagnosis and the first THA was 10.3 months for the six patients. A controlateral THA was performed for three patients after a mean interval of 23.3 months after ONFH diagnosis. Of the nine implanted prostheses, four were cemented, four were cementless, and one was resurfacing prosthesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277811     DOI: 10.1007/s10067-009-1156-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  74 in total

1.  Classification of osteonecrosis of the femoral head. Reliability, reproducibility, and prognostic value.

Authors:  A Y Plakseychuk; M Shah; S E Varitimidis; H E Rubash; D Sotereanos
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

2.  Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis.

Authors:  Clinton Baldwin; Vikki G Nolan; Diego F Wyszynski; Qian-Li Ma; Paola Sebastiani; Stephen H Embury; Alice Bisbee; John Farrell; Lindsay Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

3.  The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.

Authors:  Kuo-An Lai; Wun-Jer Shen; Chyun-Yu Yang; Chung-Jung Shao; Jui-Ting Hsu; Ruey-Mo Lin
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

Review 4.  Non-traumatic avascular necrosis of the femoral head.

Authors:  M A Mont; D S Hungerford
Journal:  J Bone Joint Surg Am       Date:  1995-03       Impact factor: 5.284

5.  Osteonecrosis in six HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Aurélie C Molia; Christophe Strady; Christine Rouger; Isabelle M Beguinot; Jean-Luc Berger; Thierry C Trenque
Journal:  Ann Pharmacother       Date:  2004-10-26       Impact factor: 3.154

6.  Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.

Authors:  Murielle Mary-Krause; Eric Billaud; Isabelle Poizot-Martin; Anne Simon; Catherine Dhiver; Caroline Dupont; Dominique Salmon; Laurent Roudiere; Dominique Costagliola
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

7.  Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study.

Authors:  S Agarwala; D Jain; V R Joshi; A Sule
Journal:  Rheumatology (Oxford)       Date:  2004-11-30       Impact factor: 7.580

8.  Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan.

Authors:  Ya-Chi Ho; Tiffany T F Shih; Yu-Hui Lin; Chin-Fu Hsiao; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Huei Sheng; Hsin-Yun Sun; Chien-Ching Hung; Shan-Chwen Chang
Journal:  Jpn J Infect Dis       Date:  2007-11       Impact factor: 1.362

9.  Osteonecrosis in HIV-infected persons: radiographic findings delay clinical diagnosis.

Authors:  Mark D Johnson; Catherine F Decker
Journal:  AIDS Read       Date:  2008-03

10.  Natural history of nontraumatic avascular necrosis of the femoral head.

Authors:  K Ohzono; M Saito; K Takaoka; K Ono; S Saito; T Nishina; T Kadowaki
Journal:  J Bone Joint Surg Br       Date:  1991-01
View more
  10 in total

1.  Avascular necrosis of the femoral head in HIV positive patients-an assessment of risk factors and early response to surgical treatment.

Authors:  L Chokotho; W J Harrison; N Lubega; N C Mkandawire
Journal:  Malawi Med J       Date:  2013-06       Impact factor: 0.875

2.  Does HIV infection increase the risk of perioperative complications after THA? A nationwide database study.

Authors:  Qais Naziri; Matthew R Boylan; Kimona Issa; Lynne C Jones; Harpal S Khanuja; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2015-02       Impact factor: 4.176

3.  Risk of Complications After THA Increases Among Patients Who Are Coinfected With HIV and Hepatitis C.

Authors:  Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan Vigdorchik; Richard Iorio; Ran Schwarzkopf
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

4.  Surgery of the femur in HIV positive patients: a retrospective review from 2005 to 2011.

Authors:  F Cummins; B Ramasubbu; T McCarthy; C Bergin; P P Grieve
Journal:  Ir J Med Sci       Date:  2014-06-11       Impact factor: 1.568

5.  Diagnosis of human immunodeficiency virus following femoral head harvest post-total hip arthroplasty.

Authors:  Kunal Mohan; Prasad Ellanti; Andrew Moriarity; Niall Hogan
Journal:  J Surg Case Rep       Date:  2018-06-15

6.  Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.

Authors:  Kalilou Diallo; Bruce Shinga Wembulua; Mohamadou Aidara; Armel Alleyo; Noel Magloire Manga
Journal:  J Med Case Rep       Date:  2021-12-18

7.  Total Joint Arthroplasty in HIV-Positive Patients in Malawi: Outcomes from the National Arthroplasty Registry of the Malawi Orthopaedic Association.

Authors:  Simon Matthew Graham; Luke Render; Chipiliro Moffat; Nicholas Lubega; Nyengo Mkandawire; Sven Young; William J Harrison
Journal:  JB JS Open Access       Date:  2021-11-04

8.  Early Outcomes of Primary Total Hip Arthroplasty for Osteonecrosis of the Femoral Head in Patients with Human Immunodeficiency Virus in China.

Authors:  Chang-Song Zhao; Xin Li; Qiang Zhang; Sheng Sun; Ru-Gang Zhao; Juan Cai
Journal:  Chin Med J (Engl)       Date:  2015-08-05       Impact factor: 2.628

9.  Osteonecrosis of the femoral head in people living with HIV: anatomopathological description and p24 antigen test.

Authors:  Ana Lucia L Munhoz Lima; Priscila Rosalba Oliveira; Vladimir C Carvalho; Alexandre Leme Godoy-Santos; Leandro Ejnisman; Claudia R Oliveira; David E Uip; Maria Irma S Duarte
Journal:  HIV AIDS (Auckl)       Date:  2018-05-25

10.  Previously unexplored etiology for femoral head necrosis: Metagenomics detects no pathogens in necrotic femoral head tissue.

Authors:  Chao Liu; Wei Li; Chao Zhang; Feng Pang; Da-Wei Wang
Journal:  World J Clin Cases       Date:  2022-03-06       Impact factor: 1.337

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.